ERBB2 and breast carcinoma: This discrepancy might be explained by patients with advanced breast cancer in earlier studies including the HER2-positive subtype and the likely superiority of Duomeisu® to DOXIL® (Ortho Biotech Products, L.P.)or Caelyx® (Janssen-Cilag International NV) though Duomeisu® was demonstrated to be bioequivalent to Caelyx® [44].